step 9 semaglutide 2.4 mg efficacy and safety in people with obesity and knee osteoarthritis: Results: from the randomised clinical trial step 9 semaglutide Effect of

Specific triggers for medical consultation include achieving less than 5% body weight reduction after reaching the maintenance dose (for Wegovy, after 12 weeks at 2.4 mg as per FDA labeling), prolonged weight loss plateau despite adherence, or intolerable side effects preventing dose escalation to therapeutic levels

it may only be used lawfully within an authorised clinical trial or MHRA-regulated framework

Some patients benefit from keeping a food diary to identify patterns between dietary choices and symptom severity

Please note the dose of your medication will be labeled

Many doctors prescribe ondansetron as a standing prescription throughout treatment